currently recruiting studies

Crohn's disease - McMaster Exclusion Diet

PI:  Dr. Neeraj Narula

Contact: Cindy James

jamesc5@mcmaster.ca 

A study of a novel diet designed specifically for patients with Crohn's disease.  The diet is designed to remove items which may increase "gut leakiness".

Crohn's disease - Fecal Microbiota Transplantation

PI:  Dr. Paul Moayyedi

Contact: Melanie Wolfe

wolfe@hhsc.ca 

A prospective, multicenter, randomized controlled trial comparing fecal microbiota transplantation (FMT) to placebo in the treatment of mild to moderate Crohn’s disease

Pouchitis - Fecal Microbiota Transplantation

PI:  Dr. Neeraj Narula

Contact: Peter Habashi

habashp@hhsc.ca 

A prospective, multicenter, randomized controlled trial comparing fecal microbiota transplantation (FMT) to placebo in the treatment of active pouchitis

Crohn's disease - Gilead GS-US-419-3895 

PI:  Dr. John Marshall

Contact: Mitzi L 

lawren@mcmaster.ca 

Combined Phase 3, Double-blind, Randomized, Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderately to Severely Active Crohn’s Disease.

All IBD - IMAGINE

PI:  Dr. Paul Moayyedi

Contact: Melanie Wolfe 

wolfe@hhsc.ca 

IMAGINE’s Mind and Gut Interactions Cohort is a prospective observational cohort study looking at the interactions between inflammation, gut bacteria, and diet in order to better treat Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD, which includes both ulcerative colitis and Crohn’s disease), and to understand their link to mental health. www.imaginespor.com

Crohn's disease - Exclusive Enteral Nutrition and Prednisone 

PI:  Dr. Maria Ines Pinto-Sanchez

Contact: Teresa B

balartm@mcmaster.ca

A randomized controlled trial to investigate the effect of exclusive enteral nutrition in addition to different regimes of corticosteroid therapy (Prednisone) compared to corticosteroids alone in decreasing disease activity and improving quality of life in patients with Crohn's disease.

Crohn's disease - Qu Biologics QBECO-CD-02

PI:  Dr. John Marshall

Contact: Mitzi L 

lawren@mcmaster.ca 

A Phase 2, Multi-center, Randomized, Double-Blind, Placebo-Controlled Study for the Induction and Maintenance of Clinical and Endoscopic Remission in Subjects with Moderate to Severe Crohn’s Disease

Crohn's disease - Abbvie PRADA

PI:  Dr. John Marshall

Contact: Mitzi L 

lawren@mcmaster.ca 

A Cohort Study to Evaluate the Effectiveness of Drug Concentrations in Predicting Recapture of Response with Weekly ADAlimumab in Crohn’s Disease Subjects with Secondary Loss of Response (PRADA)

Ulcerative colitis - A study of antibiotics vs placebo in addition to Fecal Microbiota Transplantation

PI:  Dr. Paul Moayyedi

Contact: Melanie Wolfe 

wolfe@hhsc.ca  

A Phase 3, Single-center, Randomized, Double-Blind, Placebo-Controlled Study for the Induction of Ulcerative Colitis in Subjects with Mild, Moderate to Severe Ulcerative Colitis.  All subjects receive fecal microbiota transplantation for induction of remission of ulcerative colitis.  Patients are randomized to receive antibiotics or placebo prior to receiving fecal microbiota transplantation.

Ulcerative colitis - Gilead GS-US-418-3898

PI:  Dr. John Marshall

Contact: Mitzi L 

lawren@mcmaster.ca 

Combined Phase 2B/3, Double-Blind, Randomized Placebo-Controlled Studies Evaluating the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Subjects with Moderate to Severely Active Ulcerative Colitis